AR045663A1 - Derivados de quinazolina - Google Patents
Derivados de quinazolinaInfo
- Publication number
- AR045663A1 AR045663A1 ARP040103321A ARP040103321A AR045663A1 AR 045663 A1 AR045663 A1 AR 045663A1 AR P040103321 A ARP040103321 A AR P040103321A AR P040103321 A ARP040103321 A AR P040103321A AR 045663 A1 AR045663 A1 AR 045663A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- group
- alkoxy
- heterocyclyl
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical class N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 36
- 229910052757 nitrogen Inorganic materials 0.000 abstract 18
- -1 carboxy, carbamoyl Chemical group 0.000 abstract 14
- 125000001424 substituent group Chemical group 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 12
- 239000001257 hydrogen Substances 0.000 abstract 12
- 125000000217 alkyl group Chemical group 0.000 abstract 11
- 125000000623 heterocyclic group Chemical group 0.000 abstract 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 10
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 10
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 8
- 125000005236 alkanoylamino group Chemical group 0.000 abstract 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 8
- 150000002367 halogens Chemical class 0.000 abstract 8
- 229910052760 oxygen Inorganic materials 0.000 abstract 8
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 abstract 6
- 125000004423 acyloxy group Chemical group 0.000 abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000001589 carboacyl group Chemical group 0.000 abstract 6
- 125000005115 alkyl carbamoyl group Chemical group 0.000 abstract 5
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 abstract 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000003302 alkenyloxy group Chemical group 0.000 abstract 3
- 125000005133 alkynyloxy group Chemical group 0.000 abstract 3
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 238000003780 insertion Methods 0.000 abstract 2
- 230000037431 insertion Effects 0.000 abstract 2
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 2
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- NFGODEMQGQNUKK-UHFFFAOYSA-M [6-(diethylamino)-9-(2-octadecoxycarbonylphenyl)xanthen-3-ylidene]-diethylazanium;chloride Chemical group [Cl-].CCCCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1C1=C2C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C21 NFGODEMQGQNUKK-UHFFFAOYSA-M 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005724 cycloalkenylene group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000464 thioxo group Chemical group S=* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Abstract
Procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en la fabricación de un medicamento para proveer un efecto antiproliferativo. Los derivados de quinazolina de fórmula (1) están destinados al tratamiento de enfermedades tales como determinados cánceres mediados por las tirosina quinasas del receptor erbB, particularmente tirosina quinasa EGFR. Reivindicación 1: Un derivado de quinazolina caracterizado porque responde a la fórmula (1); en donde: R1 se selecciona entre hidrógeno, hidroxi, (C1-6)alcoxi, (C2-6)alqueniloxi, (C2-6)alquiniloxi, o entre un grupo de la fórmula: Q2-X3, en donde X3 es un enlace directo o es O, y Q es (C3-7)cicloalquilo, (C3-7)cicloalquil-(C1-6)alquilo, (C3- 7)cicloalquenilo, (C3-7)cicloalquenil-(C1-6)alquilo, heterociclilo o heterociclil-(C1-6)alquilo, y en donde los átomos de carbono contiguos en cualquier cadena (C2-6)alquileno dentro de un sustituyente R1 están opcionalmente separados por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R3), CO, CH(OR3), CON(R3), N(R3)CO, SO2N(R3), N(R3)SO2, CH=CH y C:::C en donde R3 es hidrógeno o (C1-6)alquilo, y en donde cualquier grupo CH2=CH- o HC:::C- dentro de un sustituyente R1 opcionalmente tiene en la posición terminal CH2= o HC:::C un sustituyente seleccionado entre halógeno, carboxi, carbamoilo, (C1-6)alcoxicarbonilo, N-(C1-6)alquilcarbamoilo, N,N-di-[(C1-6)alquil]carbamoilo, amino-(C1-6)alquilo, (C1- 6)alquilamino-(C1-6)alquilo y di-[(C1-6)alquil]amino-(C1-6)alquilo, o entre un grupo de fórmula Q3-X4-, en donde X4 es un enlace directo o se selecciona entre CO y N(R4)CO, en donde R4 es hidrógeno o (C1-6)alquilo, y Q3 es heterociclilo o heterociclil-(C1-6)alquilo, y en donde cualquier grupo CH2 o CH3 dentro de un sustituyente R1, a excepción de un grupo CH2 dentro de un anillo heterociclilo, tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o (C1-6)alquilo o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, sulfamoilo, oxo, tioxo, (C1-6)alcoxi, (C1-6)alquiltio, (C1-6)alquilsulfinilo, (C1-6)alquilsulfonilo, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C1- 6)alcoxicarbonilo, -N-(C1-6)alquilcarbamoilo, N,N-di-[(C1-6)alquil]carbamoilo, (C2-6)alcanoilo, (C2-6)alcanoiloxi, (C2-6)alcanoilamino, N-(C1-6)alquil-(C2-6)alcanoilamino, N(C1-6)alquilsulfamoilo, N,N-di-[(C1-6)alquil]sulfamoilo, (C1- 6)alcansulfonilamino y N-(C1-6)alquil-(C1-6)alcansulfonilamino, o entre un grupo de la fórmula :-X5-Q4, en donde X5 es un enlace directo o se selecciona entre O, S, SO, SO2, N(R5), CO, CH(OR5), CON(R5), N(R5)CO, SO2N(R5), N(R5)SO2, C(R5)2O, C(R5)2S y C(R5)2N(R5), en donde R5 es hidrógeno o (C1-6)alquilo, y Q4 es (C3-7)cicloalquilo, (C3-7)cicloalquil-(C1-6)alquilo,(C3-7)cicloalquenilo, (C3-7)cicloalquenil-(C1-6)alquilo, heterociclilo o heterociclil-(C1-6)alquilo, y en donde cualquier grupo heterociclilo dentro de un sustituyente en R1 tiene opcionalmente uno o más sustituyentes, que pueden ser iguales o diferentes, seleccionados entre halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, formilo, mercapto, sulfamoilo, (C1-6)alquilo, (C2-8)alquenilo, (C2-8)alquinilo, (C1-6)alcoxi, (C2-6)alqueniloxi, (C2-6)alquiniloxi, (C1-6)alquiltio, (C1-6)alquilsulfinilo, (C1-6)alquilsulfonilo, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C1-6)alcoxicarbonilo, N-(C1- 6)alquilcarbamoilo, N,N-di-[C1-6)alquil]carbamoilo, N-(C1-6)alquilsulfamoilo, N,N-di-[(C1-6)alquil]sulfamoilo, (C2-6)alcanoilo, (C2-6)alcanoiloxi, (C2-6)alcanoilamino, N-(C1-6)alquil-(C2-6)alcanoilamino, N-(C1-6)alquilsulfamoilo, N,N-di-[(C1- 6)alquil]sulfamoilo, (C1-6)alcansulfonilamino, y N-(C1-6)alquil-(C1-6)alcansulfonilamino, o entre un grupo de fórmula: -X6-R6, en donde X6 es un enlace directo o se selecciona entre O, N(R7) y C(O), en donde R7 es hidrógeno o (C1-6)alquilo, y R6 es halógeno-(C1-6)alquilo, hidroxi-(C1-6)alquilo, carboxi-(C1-6)alquilo, (C1-6)alcoxi-(C1-6)alquilo, ciano-(C1-6)alquilo, amino-(C1-6)alquilo, (C1-6)alquilamino-(C1-6)alquilo, di-[(C1-6)alquil]amino-(C1-6)alquilo, (C2-6)alcanoilamino-(C1-6)alquilo, (C1- 6)alcoxicarbonilamino-(C1-6)alquilo, carbamoil-(C1-6)alquilo, N-(C1-6)alquilcarbamoil-(C1-6)alquilo, N,N-di-[(C1-6)alquil]carbamoil-(C1-6)alquilo, (C2-6)alcanoil-(C1-6)alquilo o (C1-6)alcoxicarbonil-(C1-6)alquilo, y en donde cualquier grupo heterociclilo dentro de un sustituyente en R1 opcionalmente tiene 1 ó 2 sustituyentes oxo o tioxo; b es 1, 2, 3, 4 ó 5; cada R2, que puede ser igual o diferente en cada caso, se selecciona entre halógeno, ciano, nitro, hidroxi, amino, carboxi, carbamoilo, sulfamoilo, trifluorometilo, (C1-6)alquilo, (C2-8)alquenilo, (C2-8)alquinilo, (C1-6)alcoxi, (C2-6)alqueniloxi, (C2-6)alquiniloxi, (C1-6)alquiltio, (C1-6)alquilsulfinilo, (C1-6)alquilsulfonilo, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C1-6)alcoxicarbonilo, N-(C1-6)alquilcarbamoilo, N,N-di-[C1-6)alquil]carbamoilo, (C2-6)alcanoilo, (C2-6)alcanoiloxi, (C2-6)alcanoilamino, N-(C1-6)alquil-(C2-6)alcanoilamino, N-(C1-6)alquilsulfamoilo, N,N-di-[(C1-6)alquil]sulfamoilo, (C1- 6)alcansulfonilamino, y N-(C1-6)alquil-(C1-6)alcansulfonilamino y un grupo de la fórmula: -X7-R8, en donde X7 es un enlace directo o se selecciona entre O, y N(R), en donde R9 es hidrógeno o (C1-6)alquilo, y R8 es halógeno-(C1-6)alquilo, hidroxi-(C1- 6)alquilo, (C1-6)alcoxi-(C1-6)alquilo, ciano-(C1-6)alquilo, amino-(C1-6)alquilo, (C1-6)alquilamino-(C1-6)alquilo, di-[(C1-6)alquil]amino-(C1-6)alquilo, (C2-6)alcanoilamino-(C1-6)alquilo o (C1-6)alcoxicarbonilamino-(C1-6)alquilo; Q1 es piperidinilo; a es 0, 1, 2, 3, ó 4; cada W, que puede ser igual o diferente en cada caso, se selecciona entre halógeno, trifluorometilo, ciano, nitro, hidroxi, oxo, amino, formilo, mercapto, (C1-6)alquilo, (C1-6)alcoxi, (C1-6)alquiltio, (C1-6)alquilsulfinilo, (C1- 6)alquilsulfonilo, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C2-6)alcanoilo, (C2-6)alcanoiloxi y entre un grupo de la fórmula: -X8-R10, en donde X8 es un enlace directo o se selecciona entre O, CO, SO2 y N(R11), en donde R11 es hidrógeno o (C1- 6)alquilo, y R10 es halógeno-(C1-6)alquilo, hidroxi-(C1-6)alquilo, (C1-6)alcoxi-(C1-6)alquilo, ciano-(C1-6)alquilo, amino-(C1-6)alquilo, N-(C1-6)alquilamino-(C1-6)alquilo o N,N-di-[(C1-6)alquil]amino-(C1-6)alquilo; X1 se selecciona entre CO y SO2; X2 es un grupo de la fórmula -(CR12R13)p-(Q5)m(CR14R15)q, en donde m es 0 ó 1, p es 0, 1, 2, 3 ó 4 y q es 0, 1, 2, 3 ó 4, cada uno de R12, R13, R14 y R15, que puede ser igual o diferente en cada caso, se selecciona entre hidrógeno, (C1-6)alquilo, amino, (C1-6)alquilamino y di-[(C1-6)alquil]amino, y Q5 se selecciona entre (C3-7)cicloalquileno y (C3-7)cicloalquenileno, y en donde cualquier grupo CH2 o CH3 dentro de un grupo X2, tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o (C1-6)alquilo o un sustituyente seleccionado entre hidroxi, ciano, amino, (C1-6)alcoxi, (C1-6)alquilamino y di-[(C1-6)alquil]amino; Z se selecciona entre hidroxi, amino, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C1- 6)alcoxi, (C1-6)alquilsulfonilo, (C1-6)alcansulfonilamino, N-(C1-6)alquil-(C1-6)alcansulfonilamino y un grupo de la fórmula: Q6-X9-, en donde X9 es un directo o se selecciona entre O, N(R16), SO2 y SO2(NR16), en donde R16 es hidrógeno o (C1- 6)alquilo, y Q6 es (C3-7)cicloalquilo, (C3-7)cicloalquil-(C1-4)alquilo, (C3-7)cicloalquenilo, (C3-7)cicloalquenil-(C1-4)alquilo, heterociclilo o heterociclil-(C1-4)alquilo; con la salvedad de que cuando X9 es un enlace directo, Q6 es heterociclilo, y con la salvedad de que cuando m, p y q son todos 0, entonces Z es heterociclilo, y en donde los átomos de carbono contiguos en cualquier cadena (C2-6)alquileno dentro de un sustituyente Z están opcionalmente separados por la inserción en la cadena de un grupo seleccionado entre O, S, SO, SO2, N(R''), CO, -C=C- y -C=C- en donde R17 es hidrógeno o (C1-6)alquilo, y en donde cualquier grupo CH2 o CH3 dentro cualquier grupo Z, a excepción de un grupo CH2 dentro de un anillo heterociclilo, tiene opcionalmente en cada uno de dichos grupos CH2 o CH3 uno o más sustituyentes halógeno o (C1-6)alquilo o un sustituyente seleccionado entre hidroxi, ciano, amino, carboxi, carbamoilo, sulfamoilo, (C2-6)alquenilo, (C2-6)alquinilo, (C1-6)alcoxi, (C1- 6)alquiltio, (C1-6)alquilsulfinilo, (C1-6)alquilsulfonilo, (C1-6)alquilamino, di-[(C1-6)alquil]amino, N-(C1-6)alquilcarbamoilo, N,N-di-[(C1-6)alquil]carbamoilo, (C2-6)alcanoilo, (C2-6)alcanoiloxi, (C2-6)alcanoilamino, N-(C1-6)alquil-(C2- 6)alcanoilamino, N-(C1-6)alquilsulfamoilo, N,N-di[(C1-6)alquil]sulfamoilo, (C1-6)alcansulfonilamino y N-(C1-6)alquil-(C1-6)alcansulfonilamino, y en donde cualquier grupo heterociclilo dentro de un sustituyente Z tiene opcionalmente uno o más sustituyentes que pueden ser iguales o diferentes, seleccionados entre halógeno, trifluorometilo, ciano, nitro, hidroxi, amino, formilo, mercapto, (C1-6)alquilo, (C2-6)alquenilo, (C2-6)alquinilo, (C1-6)alcoxi, (C1-6)alquiltio, (C1-6)alquilsulfinilo, (C1-6)alquilsulfonilo, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C2-6)alcanoilo, (C2-6)alcanoiloxi, y entre un grupo de la fórmula: X10-R18, en donde X10 es un enlace directo o se selecciona entre O, CO, SO2 y N(R19), en donde R19 es hidrógeno o (C1-6)alquilo, y R18 es halógeno-(C1-4)alquilo, hidroxi-(C1-4)alquilo, (C1-4)alcoxi-(C1-4)alquilo, ciano-(C1-4)alquilo, amino-(C1-4)alquilo, N-(C1-4)alquilamino-(C1-6)alquilo y N,N-di-[(C1-4)alquil]amino-(C1-4)alquilo; con las siguientes salvedades: cuando el grupo 4-anilino en la fórmula (1) es 4-bromo-2-fluoroanilino o 4-cloro-2-fluoroanilino y R1 es hidrógeno o (C1-3)alcoxi, entonces a es 0 y Z se selecciona entre hidroxi, amino, (C1-6)alquilamino, di-[(C1-6)alquil]amino, (C1-6)alcoxi, (C1- 6)alquilsulfonilo, (C1-6)alcansulfonilamino, N-(C1-6)alquil-(C1-6)alcansulfonilamino, y un grupo de la fórmula: Q6-X9-; o una sal aceptable para uso farmacéutico, o un éste
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0321620.7A GB0321620D0 (en) | 2003-09-16 | 2003-09-16 | Quinazoline derivatives |
GB0406163A GB0406163D0 (en) | 2004-03-19 | 2004-03-19 | Quinazoline derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045663A1 true AR045663A1 (es) | 2005-11-02 |
Family
ID=34315440
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040103321A AR045663A1 (es) | 2003-09-16 | 2004-09-16 | Derivados de quinazolina |
Country Status (25)
Country | Link |
---|---|
US (2) | US7569577B2 (es) |
EP (1) | EP1667991B1 (es) |
JP (1) | JP4795952B2 (es) |
AR (1) | AR045663A1 (es) |
AT (1) | ATE395346T1 (es) |
AU (1) | AU2004272348B2 (es) |
BR (1) | BRPI0414489A8 (es) |
CA (1) | CA2538884C (es) |
CO (1) | CO5690594A2 (es) |
CY (1) | CY1108186T1 (es) |
DE (1) | DE602004013806D1 (es) |
DK (1) | DK1667991T3 (es) |
ES (1) | ES2305844T3 (es) |
HK (1) | HK1091480A1 (es) |
HR (1) | HRP20080329T3 (es) |
IL (1) | IL174261A0 (es) |
MX (1) | MXPA06002964A (es) |
NO (1) | NO20061322L (es) |
PL (1) | PL1667991T3 (es) |
PT (1) | PT1667991E (es) |
RU (1) | RU2378268C2 (es) |
SI (1) | SI1667991T1 (es) |
TW (1) | TW200519104A (es) |
UA (1) | UA84167C2 (es) |
WO (1) | WO2005026150A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
DE60231230D1 (de) * | 2001-11-03 | 2009-04-02 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
GB0309009D0 (en) * | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) * | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
DE602004022180D1 (de) * | 2003-09-16 | 2009-09-03 | Astrazeneca Ab | Chinazolinderivate |
GB0321648D0 (en) * | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06002963A (es) * | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
CA2541100A1 (en) * | 2003-09-16 | 2005-03-24 | Astrazenca Ab | Quinazoline derivatives |
GB0322409D0 (en) * | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) * | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
US8017321B2 (en) * | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
US20080113874A1 (en) * | 2004-01-23 | 2008-05-15 | The Regents Of The University Of Colorado | Gefitinib sensitivity-related gene expression and products and methods related thereto |
EP1713781B1 (en) * | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
ES2537631T3 (es) * | 2004-05-27 | 2015-06-10 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
US20070232607A1 (en) * | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
ATE479687T1 (de) | 2004-10-15 | 2010-09-15 | Takeda Pharmaceutical | Kinaseinhibitoren |
US7947676B2 (en) * | 2004-12-14 | 2011-05-24 | Astrazeneca Ab | Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents |
GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
EP1861094A4 (en) * | 2005-03-11 | 2014-06-11 | Univ Colorado | HISTONDEACETYLASE INHIBITORS SENSITIZE CANCER CELLS FOR EPIDERMAL GROWTH FACTOR INHIBITORS |
GB0508717D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
US20100234371A1 (en) * | 2005-08-22 | 2010-09-16 | Frank Himmelsbach | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
WO2007034144A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | 4- (ih-indazol-s-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2007034143A1 (en) * | 2005-09-20 | 2007-03-29 | Astrazeneca Ab | Quinazoline derivatives as anticancer agents |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
JP2009517450A (ja) * | 2005-12-02 | 2009-04-30 | アストラゼネカ アクチボラグ | チロシンキナーゼ阻害薬としての4−アニリノ置換キナゾリン誘導体 |
CN101321739A (zh) * | 2005-12-02 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 用作erbB酪氨酸激酶抑制剂的喹唑啉衍生物 |
CN101535279B (zh) * | 2006-09-11 | 2015-05-20 | 柯瑞斯公司 | 含锌结合基的喹唑啉基egfr抑制剂 |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
GEP20135728B (en) | 2006-10-09 | 2013-01-25 | Takeda Pharmaceuticals Co | Kinase inhibitors |
ES2444128T3 (es) | 2008-05-13 | 2014-02-24 | Astrazeneca Ab | Nueva SAL-554 |
CN102452988B (zh) | 2010-10-27 | 2016-01-27 | 中国科学院化学研究所 | 一种喹唑啉衍生物及其制备方法 |
KR101940340B1 (ko) | 2011-03-04 | 2019-01-18 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 아미노-퀴놀린 |
TWI547494B (zh) | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
AR092529A1 (es) * | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基-喹啉類 |
KR20150118152A (ko) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 퀴나졸린 |
JP7265985B2 (ja) | 2016-11-17 | 2023-04-27 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | Egfrまたはher2のエクソン20変異を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3812257A (en) | 1972-04-07 | 1974-05-21 | Sumitomo Chemical Co | Uricosuric agent |
US3971783A (en) | 1973-03-07 | 1976-07-27 | Pfizer Inc. | 4-Aminoquinazoline derivatives as cardiac stimulants |
US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
KR910006138B1 (ko) | 1986-09-30 | 1991-08-16 | 에자이 가부시끼가이샤 | 환상아민 유도체 |
US5411963A (en) | 1988-01-29 | 1995-05-02 | Dowelanco | Quinazoline derivatives |
US4921863A (en) | 1988-02-17 | 1990-05-01 | Eisai Co., Ltd. | Cyclic amine derivatives |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
EP0584222B1 (en) | 1991-05-10 | 1997-10-08 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
EP0585371B1 (en) | 1991-05-20 | 2002-04-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Aromatic oligomeric compounds useful as mimics of bioactive macromolecules |
US5441963A (en) * | 1991-12-20 | 1995-08-15 | Merrell Dow Pharmaceuticals | Potentiation of NMDA antagonists |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5395846A (en) | 1993-06-25 | 1995-03-07 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Amino Bi- and tri-carbocyclic aklane bis-aryl squalene synthase inhibitors |
US5614627A (en) | 1993-09-10 | 1997-03-25 | Eisai Co., Ltd. | Quinazoline compounds |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
CA2216796C (en) | 1995-03-30 | 2003-09-02 | Pfizer Inc. | Quinazoline derivatives |
GB9508537D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508535D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
AU5343096A (en) | 1995-04-27 | 1996-11-18 | Zeneca Limited | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
GB9515975D0 (en) | 1995-08-04 | 1995-10-04 | Zeneca Ltd | Chemical compounds |
US6127366A (en) | 1995-11-22 | 2000-10-03 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9604311D0 (en) | 1996-02-29 | 1996-05-01 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase |
EP0862435A4 (en) | 1995-11-22 | 1999-02-03 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
EP0880501A1 (en) | 1996-02-02 | 1998-12-02 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
ES2194181T3 (es) | 1996-02-13 | 2003-11-16 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de vegf. |
GB9603097D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
DK0885198T3 (da) | 1996-03-05 | 2002-03-25 | Astrazeneca Ab | 4-Anilinoquinazolinderivater |
CA2249446C (en) | 1996-04-12 | 2008-06-17 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
GB9607729D0 (en) | 1996-04-13 | 1996-06-19 | Zeneca Ltd | Quinazoline derivatives |
WO1998002434A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
CO4940469A1 (es) | 1997-03-05 | 2000-07-24 | Sugen Inc | Composicion oral de estabilidad mejorada que comprende un derivado de indolinona y una mezcla de gliceridos o esteres de polietilenglicol |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
US6200976B1 (en) | 1998-04-17 | 2001-03-13 | Boehringer Ingelheim Pharma Kg | Antithrombotic quinoxazolines |
DE19816983A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel |
WO2000009481A1 (fr) | 1998-08-11 | 2000-02-24 | Takeda Chemical Industries, Ltd. | Composes d'amide cyclique, procedes de production correspondants, intermediaires correspondants et herbicides |
WO2000010981A1 (en) | 1998-08-21 | 2000-03-02 | Parker Hughes Institute | Quinazoline derivatives |
US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
PT1131304E (pt) * | 1998-11-19 | 2003-04-30 | Warner Lambert Co | N-¬4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il|-acrilamida um inibidor irreversivel de tirosino quinases |
BR0008524A (pt) | 1999-02-27 | 2001-12-18 | Boehringer Ingelheim Pharma | Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação |
DE19908567A1 (de) | 1999-02-27 | 2000-08-31 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
US6080747A (en) | 1999-03-05 | 2000-06-27 | Hughes Institute | JAK-3 inhibitors for treating allergic disorders |
DE19911509A1 (de) * | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
YU13200A (sh) | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
PT1731511E (pt) | 1999-06-21 | 2015-11-13 | Boehringer Ingelheim Pharma | Heterociclos bicíclicos, medicamentos contendo estes compostos, a sua utilização e processos para a sua preparação |
KR100881105B1 (ko) * | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Vegf 억제제로서의 퀴나졸린 유도체 |
UA73993C2 (uk) * | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
DE10040527A1 (de) | 2000-08-18 | 2002-02-28 | Boehringer Ingelheim Pharma | Chinazoline und Verfahren zu ihrer Herstellung |
US6656946B2 (en) | 2000-08-26 | 2003-12-02 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6740651B2 (en) | 2000-08-26 | 2004-05-25 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US6653305B2 (en) | 2000-08-26 | 2003-11-25 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them |
US6617329B2 (en) | 2000-08-26 | 2003-09-09 | Boehringer Ingelheim Pharma Kg | Aminoquinazolines and their use as medicaments |
US20020082270A1 (en) | 2000-08-26 | 2002-06-27 | Frank Himmelsbach | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases |
US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
US7019012B2 (en) | 2000-12-20 | 2006-03-28 | Boehringer Ingelheim International Pharma Gmbh & Co. Kg | Quinazoline derivatives and pharmaceutical compositions containing them |
NZ516873A (en) | 2001-02-12 | 2003-11-28 | Warner Lambert Co | Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage |
WO2002066445A1 (fr) | 2001-02-21 | 2002-08-29 | Mitsubishi Pharma Corporation | Derives de la quinazoline |
US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
WO2002092578A1 (en) * | 2001-05-14 | 2002-11-21 | Astrazeneca Ab | Quinazoline derivatives |
US20040176361A1 (en) | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
GB0126433D0 (en) | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
DE60231230D1 (de) * | 2001-11-03 | 2009-04-02 | Astrazeneca Ab | Quinazolin derivate als antitumor-mittel |
DE10204462A1 (de) | 2002-02-05 | 2003-08-07 | Boehringer Ingelheim Pharma | Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse |
TWI324597B (en) | 2002-03-28 | 2010-05-11 | Astrazeneca Ab | Quinazoline derivatives |
BR0308902A (pt) * | 2002-03-30 | 2005-01-04 | Boehringer Ingelheim Pharma | 4-(n-fenilamino)-quinazolinas/quinolinas como inibidoras da tirosina cinase |
US6924285B2 (en) | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
US20040044014A1 (en) | 2002-04-19 | 2004-03-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
US20030225079A1 (en) | 2002-05-11 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy |
JPWO2003101491A1 (ja) | 2002-06-03 | 2005-09-29 | 三菱ウェルファーマ株式会社 | Her2又は/及びEGFR発現又は活性化対象に用いる予防又は/及び治療剤 |
US7560558B2 (en) | 2002-08-23 | 2009-07-14 | Kirin Beer Kabushiki Kaisha | Compound having TGFβ inhibitory activity and medicinal composition containing the same |
GB0309009D0 (en) | 2003-04-22 | 2003-05-28 | Astrazeneca Ab | Quinazoline derivatives |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
UY28441A1 (es) | 2003-07-29 | 2005-02-28 | Astrazeneca Ab | Derivados de quinazolina |
GB0317665D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Qinazoline derivatives |
DE602004022180D1 (de) | 2003-09-16 | 2009-09-03 | Astrazeneca Ab | Chinazolinderivate |
GB0321648D0 (en) | 2003-09-16 | 2003-10-15 | Astrazeneca Ab | Quinazoline derivatives |
MXPA06002963A (es) | 2003-09-16 | 2006-06-14 | Astrazeneca Ab | Derivados de quinazolina como inhibidores de cinasa de tirosina. |
ES2281007T3 (es) | 2003-09-19 | 2007-09-16 | Astrazeneca Ab | Derivados de quinazolina. |
BRPI0414735A (pt) | 2003-09-25 | 2006-11-21 | Astrazeneca Ab | derivado de quinazolina, composto, composição farmacêutica, uso de derivado de quinazolina, método para produzir um efeito anti-proliferativo em um animal de sangue quente, e, processo para a preparação de um derivado de quinazolina |
GB0322409D0 (en) | 2003-09-25 | 2003-10-29 | Astrazeneca Ab | Quinazoline derivatives |
GB0326459D0 (en) | 2003-11-13 | 2003-12-17 | Astrazeneca Ab | Quinazoline derivatives |
EP1713781B1 (en) | 2004-02-03 | 2008-11-05 | AstraZeneca AB | Quinazoline derivatives |
EP1748387B1 (en) * | 2004-05-21 | 2018-12-05 | Asahi Kasei Kabushiki Kaisha | Devices for classifying the arousal state of the eyes of a driver, corresponding method and computer readable storage medium |
US20070232607A1 (en) | 2004-06-04 | 2007-10-04 | Bradbury Robert H | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases |
-
2004
- 2004-09-13 BR BRPI0414489A patent/BRPI0414489A8/pt not_active Application Discontinuation
- 2004-09-13 RU RU2006112599/04A patent/RU2378268C2/ru not_active IP Right Cessation
- 2004-09-13 AT AT04768469T patent/ATE395346T1/de not_active IP Right Cessation
- 2004-09-13 PL PL04768469T patent/PL1667991T3/pl unknown
- 2004-09-13 JP JP2006526682A patent/JP4795952B2/ja not_active Expired - Fee Related
- 2004-09-13 WO PCT/GB2004/003923 patent/WO2005026150A1/en active IP Right Grant
- 2004-09-13 EP EP04768469A patent/EP1667991B1/en active Active
- 2004-09-13 CA CA2538884A patent/CA2538884C/en not_active Expired - Fee Related
- 2004-09-13 PT PT04768469T patent/PT1667991E/pt unknown
- 2004-09-13 AU AU2004272348A patent/AU2004272348B2/en not_active Ceased
- 2004-09-13 DE DE602004013806T patent/DE602004013806D1/de active Active
- 2004-09-13 US US10/573,090 patent/US7569577B2/en not_active Expired - Fee Related
- 2004-09-13 DK DK04768469T patent/DK1667991T3/da active
- 2004-09-13 ES ES04768469T patent/ES2305844T3/es active Active
- 2004-09-13 SI SI200430769T patent/SI1667991T1/sl unknown
- 2004-09-13 UA UAA200604148A patent/UA84167C2/ru unknown
- 2004-09-13 MX MXPA06002964A patent/MXPA06002964A/es active IP Right Grant
- 2004-09-14 TW TW093127785A patent/TW200519104A/zh unknown
- 2004-09-16 AR ARP040103321A patent/AR045663A1/es not_active Application Discontinuation
-
2006
- 2006-03-12 IL IL174261A patent/IL174261A0/en unknown
- 2006-03-23 NO NO20061322A patent/NO20061322L/no not_active Application Discontinuation
- 2006-04-10 CO CO06034940A patent/CO5690594A2/es not_active Application Discontinuation
- 2006-10-31 HK HK06111949A patent/HK1091480A1/xx not_active IP Right Cessation
-
2008
- 2008-07-07 HR HR20080329T patent/HRP20080329T3/xx unknown
- 2008-07-10 CY CY20081100724T patent/CY1108186T1/el unknown
-
2009
- 2009-06-11 US US12/482,620 patent/US20090312343A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW200519104A (en) | 2005-06-16 |
AU2004272348B2 (en) | 2008-09-04 |
UA84167C2 (ru) | 2008-09-25 |
RU2378268C2 (ru) | 2010-01-10 |
HRP20080329T3 (en) | 2008-08-31 |
CA2538884A1 (en) | 2005-03-24 |
EP1667991B1 (en) | 2008-05-14 |
CY1108186T1 (el) | 2014-02-12 |
HK1091480A1 (en) | 2007-01-19 |
SI1667991T1 (sl) | 2008-10-31 |
RU2006112599A (ru) | 2007-11-10 |
DE602004013806D1 (en) | 2008-06-26 |
PL1667991T3 (pl) | 2008-12-31 |
PT1667991E (pt) | 2008-07-14 |
DK1667991T3 (da) | 2008-08-18 |
ES2305844T3 (es) | 2008-11-01 |
EP1667991A1 (en) | 2006-06-14 |
ATE395346T1 (de) | 2008-05-15 |
BRPI0414489A (pt) | 2006-11-14 |
US7569577B2 (en) | 2009-08-04 |
NO20061322L (no) | 2006-06-15 |
CO5690594A2 (es) | 2006-10-31 |
AU2004272348A1 (en) | 2005-03-24 |
MXPA06002964A (es) | 2006-06-14 |
BRPI0414489A8 (pt) | 2019-01-15 |
WO2005026150A1 (en) | 2005-03-24 |
CA2538884C (en) | 2010-09-21 |
JP2007505872A (ja) | 2007-03-15 |
IL174261A0 (en) | 2006-08-01 |
JP4795952B2 (ja) | 2011-10-19 |
US20090312343A1 (en) | 2009-12-17 |
US20070043009A1 (en) | 2007-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045663A1 (es) | Derivados de quinazolina | |
AR045754A1 (es) | Derivados de quinazolina | |
AR059716A1 (es) | Derivados de quinolina | |
AR052315A1 (es) | Derivados de quinazolina utiles para el tratamiento de cancer | |
AR051215A1 (es) | Derivados de quinazolina | |
AR037193A1 (es) | Derivados de quinazolina, composicion farmaceutica, su uso en la fabricacion de un medicamento y procesopara preparar dicho derivado de quinazolina | |
AR033560A1 (es) | Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento, | |
AR069078A1 (es) | Derivados de piridina y pirazina | |
ES2547916T3 (es) | Terapia de combinación de inhibidores de mTOR/JAK | |
AR045752A1 (es) | Derivados de quinazolina que poseen actividad antitumoral | |
AR061132A1 (es) | Compuestos de fenilalanina, alanina y tirosina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la integrina alfa5beta1. | |
RU2433128C2 (ru) | Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера | |
AR046779A1 (es) | Derivados de pirazol, metodos para su preparacion y usos de los mismos en la fabricacion de composiciones farmaceuticas y medicamentos que los contienen con actividad inhibitoria de trk para el tratamiento o profilaxis del cancer. | |
AR055034A1 (es) | DERIVADOS DE 4 OXOQUINAZOLINAS-3-IL-BENZAMIDAS. PROCEDIMIENTOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS. | |
RU2008108939A (ru) | Замещенные имидазолы, фармацевтическая композиция, способ лечения заболевания, связанного по крайней мере с активностью ksp, способ ингибирования ksp, лекарственное средство для лечения рака | |
PT1115707E (pt) | Derivados de benzamida e seu uso como inibidores de citocina | |
HRP20140737T1 (hr) | Inhibitori hepatitis c virusa | |
PE20121442A1 (es) | Derivados de oxindol sustituido y composiciones farmaceuticas que los comprenden | |
AR045753A1 (es) | Derivados de quinazolina, proceso de obtencion, uso y composiciones farmaceuticas. | |
HRP20120399T1 (hr) | Novi sulfonilpiroli kao inhibitori hdac | |
AR032331A1 (es) | Derivados heterociclicos, procesos para su preparacion, composiciones farmaceuticas, y usos de dichos derivados en la fabricacion de medicamentos | |
AR031613A1 (es) | Derivados de piridina, un medicamento, una composicion farmaceutica, un inhibidor de la quinasa betaikappab, un medicamento anti-inflamatorio, un inmunosupresor, un medicamento para la isquemia, un medicamento anti-tumoral y el uso de dichos derivados para la preparacion de un medicamento | |
AR045762A1 (es) | Derivados de quinazolina | |
AR039203A1 (es) | Derivados de quinazolina | |
HRP20110882T1 (hr) | Ciklopenta [d] pirimidini kao inhibitori kinaze akt proteina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |